Oppenheimer Maintains Outperform on Tarsus Pharmaceuticals, Raises Price Target to $61
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Francois Brisebois maintains an Outperform rating on Tarsus Pharmaceuticals (TARS) and raises the price target from $59 to $61.
May 09, 2024 | 4:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst Francois Brisebois maintains an Outperform rating on Tarsus Pharmaceuticals and raises the price target from $59 to $61.
The increase in price target by a reputable analyst like Francois Brisebois suggests a positive outlook on Tarsus Pharmaceuticals' stock, likely leading to a short-term increase in its stock price. Analyst ratings and price target adjustments are significant indicators for investors, often resulting in stock price movements.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100